Article

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance Mechanisms

2025-01-01

Abstract excerpt

Background: Worldwide, cancer is the primary cause of mortality. Research indicates that around half of all cancer types are caused by p53 mutations or downregulation. Alternative or complementary therapy methods are, therefore, desperately needed. The relationship between p53 and the proto-oncoprotein MDM2, a ubiquitin ligase frequently overexpressed in AML that causes the degradation of p53, is an intriguing pla...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 69298f4d-99e0-5cf2-b498-6ecefac3d40e
DOI: 10.55940/medphar202567

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsDOI 10.55940/medphar202567Read

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell DeathSemantic proximity Read

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Semantic proximity Read

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity Read

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read

p53–Mdm2 inhibitors: patent review (2009 – 2010)Semantic proximity Read

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)Semantic proximity Read

Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer AgentsSemantic proximity Read